.jpg)
.png)
The Foundation of the National Lipid Association continues to work on increasing its visibility as well as efforts to increase awareness of lipid disorders and management. We are continuing to work in the area of underdiagnosed and undertreated lipid disorders.
Article By:
Associate Professor of Medicine
Washington University School of Medicine
St. Louis, MO Diplomate, American Board of Clinical Lipidology
As an acute care nurse practitioner at Orange Coast Memorial Hospital, Michelle Taylor, ACNP, MSN, loves teaching and working with her patients. Being a nurse for 27 years has given her the ability to speak to patients and explain more complex things in a way they can really understand.
Article By:
Orange Coast Memorial Hospital
Fountain Valley, CA
The Pacific Chapter of the National Lipid Association continues to be demographically and geographically diverse. We currently have 424 members (about 15 percent of the NLA membership in the U.S.) who are scattered among nine states comprising roughly 1,434,027 square miles of land. This translates into a PLA membership density of one member per 3,382 square miles.
Article By:
Knight Cardiovascular Institute
Associate Professor, Division of Endocrinology, Diabetes, and Clinical Nutrition
Oregon Health & Science University
Portland, OR
Mipomersen and lomitapide are specialty medications FDA-approved for the treatment of patients with homozygous familial hypercholesterolemia.
Article By:
Knight Cardiovascular Institute
Associate Professor, Division of Endocrinology, Diabetes, and Clinical Nutrition
Oregon Health & Science University
Portland, OR
Statins prevent atherosclerotic cardiovascular diseases (ASCVD). Hepatic injury (my patients most feared effect) occurs in ≤1 percent and is similar on placebo. Elevated hepatic transaminases typically resolve spontaneously and mostly are a result of dyslipidemia causing hepatosteatosis and/or cholelithiasis.1
Article By:
Director, Lipid-Arteriosclerosis Prevention and Treatment Clinic and Laboratory
University of Kansas
Kansas City, KA Diplomate, American Board of Clinical Lipidology
“A pessimist sees the difficulty in every opportunity; an optimist sees the opportunity in every difficulty.” – Sir Winston Churchill
Article By:
UC-Irvine Medical Center
Orange County, CA Diplomate, American Board of Clinical Lipidology
A decade ago, the lipid community was eagerly awaiting the completion of Phase III trials of torcetrapib, the first- in-class of the cholesteryl ester transfer protein (CETP) inhibitors.
Article By:
Western University of Health Sciences
Clinical Pharmacist, St. Mary Medical Center Long Beach
Pomona, CA Diplomate, Accreditation Council of Clinical Lipidology
My old professor used to say that one could expand to mediocrity or shrink to excellence.
Article By:
Tyler Heart Institute, Community Hospital of the Monterey Peninsula
Monterey, CA Diplomate, American Board of Clinical Lipidology
Some inherited lipid disorders can be recognized by the deposition of cholesterol and other lipids in lesions on the body termed xanthomas. Lipid deposition can occur in cutaneous and subcutaneous structures, including tendons, with the pattern of deposition characteristic of the underlying genetic disorder. Tuberous xanthomas are nodules frequently localized to the extensor surfaces of elbows, knees, knuckles, and buttocks.
Article By:
Associate Director, Bioanalytical Shared Resource Facility
Research Assistant Professor, Physiology & Pharmacology Department
Oregon Health & Science University
Portland, OR
Knight Cardiovascular Institute
Associate Professor, Division of Endocrinology, Diabetes, and Clinical Nutrition
Oregon Health & Science University
Portland, OR
The most significant advance in clinical lipidology and preventive cardiology in 2015 is the availability of proprotein convertase subtilisin-like kexin type 9 (PCSK9) monoclonal antibody (mAb) therapy.
Article By:
Division of Cardiology, University of California, Irvine
Past President, American Society for Preventive Cardiology
Irvine, CA
UC Irvine, School of Medicine
Co-Director, Diabetes Outpatient Clinic, UC Irvine Health
Director & Principal Investigator, Diabetes/Lipid Management & Research Center
Orange County, CA Diplomate, American Board of Clinical Lipidology